AbClon Inc is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-03	₩26,650.00	+1.14%	131,353
26-07-02	₩26,350.00	-6.73%	109,991
26-07-01	₩28,250.00	+1.62%	131,499
26-06-30	₩27,800.00	-7.49%	103,421
26-06-29	₩30,050.00	+19.01%	208,436

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-07-03			5-day change	1st Jan Change
26,650.00 ^KRW	+1.14%		+5.54%	-37.29%

06-08	Alligator partner Henlius doses first patients in HLX22 study	FW
05-22	Alligator Bioscience comments on Henlius update for HLX22	FW

Market Cap	532B 348M 304M 279M 261M 493M 33.08B 501M 3.35B 1.3B 16.25B 1.3B 1.28B 56.21B	P/E 2024	-14.5x	P/E 2025	-43.5x
Enterprise Value	494B 323M 282M 259M 242M 458M 30.72B 465M 3.11B 1.21B 15.09B 1.21B 1.19B 52.2B	EV / Sales 2024	103x	EV / Sales 2025	164x
Free-Float	80.52%	Yield 2024 *	-	Yield 2025	-

06-08	Alligator partner Henlius doses first patients in HLX22 study	FW
05-22	Alligator Bioscience comments on Henlius update for HLX22	FW
04-23	Alligator partner Henlius presents preclinical data for HLX49	FW
04-23	Alligator Bioscience Announces Preclinical Data Presentation of Hlx49 Antibody?Drug Conjugate	CI
04-07	Abclon wins 396 million won order	RE
03-09	AbClon wins 778 million won order	RE
03-02	Alligator Bioscience: First Patient Dosed in Phase 2/3 Study with HLX22 in China	FW
25-09-30	AbClon Inc. announced that it expects to receive KRW 35.999952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture Capital and other investors.	CI
25-08-27	Abclon wins 309 million won order	RE
25-05-20	Abclon Wins 354 Million Won Order	RE
25-05-19	AbClon Inc To Issue 1.4 Million Common Shares	RE
25-05-18	AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.	CI
25-05-14	Abclon Wins 307 Million Won Order	RE

06-08	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22	AQ
05-22	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22	AQ
04-23	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026	AQ
03-02	Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22	AQ
24-12-04	Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial	AQ

AbClon Inc. Stock

Stocks

A174900

KR7174900001

Pharmaceuticals

Valuation: AbClon Inc.

Chart: AbClon Inc.

Latest news : AbClon Inc.

Press Releases: AbClon Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AbClon Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+1.14%
1 week	+5.54%
Current month	-4.14%
1 month	-21.39%
3 months	-52.66%
6 months	-45.50%
Current year	-37.29%

1 week	25,050	30,300
1 month	24,400	36,850
Current year	24,400	95,800
1 year	9,770	95,800
3 years	6,810	95,800
5 years	6,810	95,800
10 years	6,810	95,800

Manager	Title	Age	Since
Jong-Seo Lee CEO	Chief Executive Officer	63	2010-06-24
Doo-Hun Kim DFI	Director of Finance/CFO	58	2024-03-27
Jong-Hoon Kim CTO	Chief Tech/Sci/R&D Officer	57	2023-03-28

Director	Title	Age	Since
Jong-Seo Lee BRD	Director/Board Member	63	-
Jung-Ho Kim BRD	Director/Board Member	62	2021-03-28
Doo-Hun Kim BRD	Director/Board Member	58	2024-03-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABCLON INC.	+1.14%	+5.54%	+129.35%	+59.39%	347M
REGENERON PHARMACEUTICALS, INC.	+4.73%	+3.38%	+19.53%	-8.89%	66.56B
UCB	-1.93%	+0.39%	+58.62%	+226.33%	56.51B
SAMSUNG BIOLOGICS CO.,LTD.	+1.07%	+42.10%	+42.10%	+42.10%	42.98B
CSL LIMITED	+3.45%	+6.04%	-49.46%	-55.91%	40.46B
BIOGEN INC.	+3.04%	+0.04%	+62.66%	-24.29%	31.91B
MODERNA, INC.	+10.01%	+18.57%	+161.59%	-34.48%	31.65B
INCYTE CORPORATION	+2.68%	+2.73%	+70.72%	+88.24%	23.35B
INNOVENT BIOLOGICS, INC.	+2.87%	+16.83%	+3.78%	+192.67%	19.46B
SWEDISH ORPHAN BIOVITRUM AB	-0.13%	+2.75%	+67.48%	+130.07%	17.18B
Average	+2.69%	+6.75%	+56.64%	+61.52%	33.04B
Weighted average by Cap.	+2.79%	+7.29%	+43.78%	+54.31%

	2024	2025
Net sales	2.34B 1.53M 1.34M 1.23M 1.15M 2.17M 146M 2.2M 14.76M 5.73M 71.49M 5.74M 5.62M 247M	4.71B 3.08M 2.7M 2.47M 2.31M 4.37M 293M 4.44M 29.73M 11.55M 144M 11.57M 11.31M 498M
Net income	-16.3B -10.66M -9.32M -8.56M -7.99M -15.13M -1.01B -15.36M -103M -39.96M -498M -40M -39.12M -1.72B	-17.91B -11.71M -10.24M -9.4M -8.77M -16.62M -1.11B -16.87M -113M -43.89M -547M -43.94M -42.98M -1.89B
Net Debt	-4.61B -3.02M -2.64M -2.42M -2.26M -4.28M -287M -4.34M -29.09M -11.3M -141M -11.32M -11.07M -488M	-37.93B -24.8M -21.69M -19.91M -18.58M -35.19M -2.36B -35.73M -239M -92.96M -1.16B -93.07M -91.02M -4.01B